The distal splenorenal shunt (DSRS) was compared with the side-to-side portacaval shunt (PCS) in 93 prospectively matched patients with portal hypertension. After 38 months mean follow-up the two shunts had a different incidence of acute encephalopathy (22% in PCS group and 33% in DSRS group) and chronic encephalopathy (35% in PCS group and 17% in DSRS group), but the difference was not statistically significant. However, the only cases of severe and disabling chronic encephalopathy arose after PCS (p = 0.049). Acuarial curves of chronic encephalopathy showed that the maximum rate of encephalopathy (18%) in the DSRS group was reached 27 months after shunt surgery, whereas this value was reached and passed in PCS group only 4 months after shunt. Chronic encephalopathy occurred for a total duration of 20.1 months after PCS and only 11.1 months after DSRS (p = 0.003) and occupied 46 
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P5 ORTAL-SYSTEMIC SHUNTS, removing portal hypertension, represent the only definitive treatment for the prevention of variceal rebleeding.' However, suppression of hepatopetal flow could cause the appearance of hepatic encephalopathy (HE) and liver function deterioration.2 Distal splenorenal shunt (DSRS), first proposed by Warren et al. in Materials and Methods Between January 1980 and June 1984, 152 adult patients were submitted to portal-systemic shunt for portal hypertension at the First Surgical Clinic of the University ofMilan. Ninety-three patients were selected for this study on the basis of the following criteria: (1) biopsydocumented cirrhosis; (2) at least one episode of upper gastrointestinal bleeding caused by esophageal varices and confirmed by endoscopy; (3) proof of hepatopetal portal blood flow during the venous phase of the superior mesenteric angiography; (4) angiographical availability to perform both the shunts; (5) (Fig. 1) showed that the maximum rate of HE in DSRS group (18%) was reached 27 months after shunt surgery, whereas this value was reached and passed only 4 months after PCS. The 16 patients in the PCS group experienced a mean of 20. 1 months (± 14.9) with chronic HE, whereas the mean for the seven patients in the DSRS group was only 1 1.1 months (±8. 1) (p = 0.003). These 16 PCS patients had 46 .3% (±30%) of their follow-up period with chronic HE, whereas the seven DSRS patients had only 18.7% (±14.6%). This difference is highly significant (p = 0.0001). Figure 2 demonstrates the mean indices of liver function calculated for the two surgical groups during the follow-up period. The The results of the current study showed that the quality of life after DSRS is superior to that after PCS. This finding is based on the different behavior of chronic HE in the two groups regarding to incidence, seriousness, onset, and duration. First, after a follow-up of at least 2 years only 17% of DSRS patients have experienced chronic HE, as contrasted to 35% of PCS patients. This difference, however, was not statistically significant, but it seems to be clinically important. The However, these can be considered borderline cases in whom it is possible (at least theoretically) to separate the altered portal hemodynamic effect from the impaired liver function. In the majority of cases, this is very difficult. In this study the cumulative curve of patients free of chronic HE (Fig. 1) after PCS seems to have two components: a rapid initial slope for 12 months after discharge followed by a more gentle slope thereafter, whereas the curve after DSRS showed a more progressive slope from beginning to end. The rapid development of chronic HE after PCS could be due to the improvised loss of portal perfusion contributing to hepatocellular damage (Fig. 2) . However, the progressive development of chronic HE after DSRS could be due to the evolutive chronic disease. It is known that loss of liver volume occurs in unoperated patients and probably represents the natural history of disease. 39 Portacaval shunt diverts portal venous flow away from the liver, contributing to liver failure. Furthermore, a toxic substance or substances from the gastrointestinal tract bypass their normal metabolic site in the liver and reach the brain in high concentrations, where they produce cerebral dysfunction. Finally, total portalsystemic shunt causes increased ammonia absorption from the small and large bowel due to decompression of the splanchnic circulation.
DSRS should represent optimal surgical therapy because postoperative portal perfusion and superior mesenteric-portal venous hypertension are maintained; these aim to preserve liver cell function in the already impaired liver of cirrhotics.12 However, six randomized controlled trials have demonstrated conflicting results regarding subsequent incidence of HE.9"' [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] 16 The lack of a clearly positive effect on HE after DSRS may be due to (besides afore-mentioned natural history of liver disease) the progressive loss of shunt selectivity. [40] [41] [42] [43] In our experience of 1 
